Stem cells derived from human fetuses will be injected into the eyes of a dozen patients suffering from age-related macular degeneration, under a clinical trial approved early this year by the U.S. Food and Drug Administration.
In mid-May, StemCells Inc. reported preliminary success in clinical safety trials with the same product on European patients with spinal injuries — the holy grail of potential stem-cell treatments. These trials are designed only to determine if the stem cells trigger tumors or immune reactions.
But the California-based, publicly traded firm isn’t touting the source of its designer stem cell, HuCNS-SC. On its website, it describes the product as “tissue-derived...READ MORE